Jean L Koff
Overview
Explore the profile of Jean L Koff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nastoupil L, Andersen C, Ayers A, Wang Y, Habermann T, Chihara D, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966020
Introduction: Clinical trials provide meaningful data regarding the safety and efficacy of novel therapies but there is often a lag between the time of new drug approval and information on...
2.
Yamshon S, Koff J, Larson M, Kahl B, Casulo C, Lossos I, et al.
Am J Hematol
. 2025 Feb;
100(4):606-615.
PMID: 39918101
Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is a commonly used chemoimmunotherapy regimen for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but there are limited real-world data. In a multicenter...
3.
Flowers C, Anantha R, Leautaud V, Desai P, Donald C, Hildebrandt M, et al.
Blood Cancer Discov
. 2025 Feb;
6(2):79-93.
PMID: 39898759
This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need...
4.
Day J, Larson M, Durani U, Koff J, Wang Y, Habermann T, et al.
Blood Adv
. 2024 Nov;
9(5):1013-1023.
PMID: 39602301
Progression of disease within 24 months of initial immunochemotherapy (POD24) is a negative prognostic factor for patients with follicular lymphoma (FL). There is no standard treatment after POD24. Assembling an...
5.
Zhong Z, Quinones-Perez M, Dai Z, Juarez V, Bhatia E, Carlson C, et al.
Nat Mater
. 2024 Nov;
24(2):297-311.
PMID: 39506098
Antibodies are produced when naive B cells differentiate into plasma cells within germinal centres (GCs) of lymphoid tissues. Patients with B cell lymphoma on effective immunotherapies exhibit diminished antibody production,...
6.
Bommier C, Link B, Gysbers B, Maurer M, Larson M, Khurana A, et al.
Blood Adv
. 2024 Sep;
8(23):5939-5948.
PMID: 39321424
Marginal zone lymphoma (MZL) includes extranodal MZL (EMZL), splenic MZL (SMZL), and nodal MZL (NMZL) subtypes. Histologic transformation (HT) to large B-cell lymphomas is well documented but with a large...
7.
Koff J, Karadkhele G, Switchenko J, Rupji M, Little K, Larsen C
Front Transplant
. 2024 Jul;
2:1280993.
PMID: 38993886
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening malignancy that arises in the setting of immunosuppression (IS) after solid organ transplant. IS regimens containing belatacept have been associated...
8.
Britto L, Balasubramani D, Desai S, Phillips P, Trehan N, Cesarman E, et al.
Adv Healthc Mater
. 2024 Jun;
14(5):e2401192.
PMID: 38837879
Activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is a subtype associated with poor survival outcomes. Despite identifying therapeutic targets through molecular characterization, targeted therapies have limited success. New strategies...
9.
Lin H, Uricoli B, Freeman R, Hossian A, He Z, Anderson J, et al.
Adv Healthc Mater
. 2024 Jan;
13(14):e2302425.
PMID: 38245855
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated...
10.
Cerhan J, Maurer M, Link B, Feldman A, Habermann T, Jaye D, et al.
Am J Hematol
. 2024 Jan;
99(3):408-421.
PMID: 38217361
To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/)....